| CEO Name | Gilmore O'Neill |
| Nationality | Ireland |
| Net Worth Estimation | $10 million |
Gilmore O'Neill's estimated net worth of around $10 million is primarily derived from his compensation, stock awards, and equity holdings as CEO of Editas Medicine, as well as previous executive roles at Biogen and Sarepta Therapeutics. Public filings and market performance of Editas Medicine's shares inform this valuation.
Gilmore O'Neill, CEO of Editas Medicine in the biotechnology sector, has an estimated net worth of $10,000,000, which is the minimum within the $10,000,000 to $80,000,000 range. This places his net worth at approximately 12.5% of the maximum estimated CEO net worth in this field.
Business Category: Biotechnology
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 80000000 USD
Gilmore O'Neill Performance in Editas Medicine
Gilmore O'Neill, CEO of Editas Medicine, drives strategic leadership focusing on innovative gene editing technologies and has strengthened decision-making processes that align with advancing CRISPR-based therapies. His performance has accelerated clinical pipeline development and secured critical partnerships and funding, enhancing the company's market position. O'Neill's impact is marked by significant progress in therapeutic candidates and increased investor confidence, solidifying Editas Medicine's role in the gene editing industry.
Latest News
Editas Medicine CEO Gilmore O'Neill Leads Strategic In Vivo Gene Editing Advances
Editas Medicine, under CEO Gilmore O'Neill since mid-2022, focuses on in vivo gene editing therapies targeting diseases like thalassemia, sickle cell, and familial hypercholesterolemia, aiming to declare two drug candidates by mid-2025 and file INDs in 2026. O'Neill, who succeeded Jim Mullen, has prioritized a strong translational medicine team and capital efficiency, securing funding through Q2 2027 while progressing high-impact clinical programs such as EDIT-401 for LDL cholesterol reduction.
Source: http://www.investing.com/news/transcripts/editas-medicine-at-bofa-securities-2025-in-vivo-gene-editing-focus-93CH-4043658